“Professor Hellström received her MD in 1986 and her PhD in 1997; she became a specialist in ophthalmology in 2004. Since 2004 she is a full Professor of Pediatric Ophthalmology at the Sahlgrenska Academy, University of Gothenburg.
Professor Hellström is a leading researcher within the field of experimental ophthalmology and her scientific achievements have attracted worldwide attention. For example, she pioneered the concept that low levels of the growth factor IGF-I can cause blindness in preterm infants. Furthermore, her research group has developed a web based screening tool for the prediction of retinopathy (WINROP), resulting in less stressful examinations for these patients. This tool is now being used routinely in clinical practice worldwide. Professor Hellström is the recipient of several national and international prizes and awards: In 1997 she received an award from the Knut and Alice Wallenberg Foundation for “promising female researcher”, and in 2012 she was awarded the Athena Prize – Sweden’s most prestigious prize for clinical research.
In her clinical role, Professor Hellström is a consultant physician in pediatric ophthalmology at the Sahlgrenska University hospital. She also heads the Sahlgrenska Center for Pediatric Ophthalmology Research at the Institute of Neuroscience and Physiology at the University of Gothenburg, which is a strategic research centre focused on vascular and neural development research. Under Professor Hellström’s leadership, the Center has integrated basic research with clinical research and is today a translational center in which clinical issues and biomedical expertise meet and create new ways of studying the mechanisms behind disease, which may lead to new treatments. With Professor Hellström as the leading researcher, the Center has now taken one drug from “bench to bedside”; the concept of treating preterm infants with IGF-I was taken over by Shire in 2013 that has finalised a Phase II multicentre study, and are now planning a phase IIb study with chronic respiratory failure as primary outcome. The center is at present conducting a randomised clinical trial with fatty acid supplement (AA:DHA) to preterm infants. Her research group has developed a computerized program to predict proliferative disease by monitoring weekly biomarkers, reducing stressful screening examinations in 25-50% of the preterm infants (Löfqvist et al Archives of Ophthalmology 2006). The article rendered an editorial “Screening for Retinopathy of Prematurity- The Promise of New Approaches. The algorithm has now been further developed (web based) and is now being used in clinical practice worldwide. Lately, the research group of Prof Hellström has started to develop a digital e-health solution with the aim to minimize blindness worldwide in preterm born children.
15:15 - 16:00
- Användbarhet / Appar / Dokumentation / Etik / Exempel från verkligheten (goda/dåliga) / Informationssäkerhet / Innovativ/forskning / Juridik / Kommun / Nytta/effekt / Patientsäkerhet / Personcentrering, samverkan över organisationsgränser / Styrning / Test/validering / Uppföljning/Nulägesbeskrivning / Välfärdsutveckling
- Beslutstöd - metoder / graviditet
- Chef/Beslutsfattare / Forskare (även studerande) / Omsorgspersonal / Patientorganisationer/Brukarorganisationer / Politiker / Studerande / Tekniker/IT/Utvecklare / Verksamhetsutveckling / Vårdpersonal
In recent years in some regions, twice as many children have been treated because of ROP. At the same time, Löf (patientförsäkringen) has initiated a study as they have noticed that more infants have become blind due to ROP and that they suspected that the cause could be found in the screening process.
Known shortcomings are that, despite national guidelines, examination results are not recorded in a standardized manner. In addition, results are handled by several categories of staff before being added to the analogue chart. Responsible neonatologists also need access to a standardized documentation of disease development in order not to delay examinations and treatment. We believe the solution is a standardized documentation of disease development implemented in a mobile-health platform, including a digital protocol, remote monitoring and self-management. In the mobile-health platform the doctors will use AI both to predict a) the patient’s ROP score and b) probability of need of laser treatment. The guardians will use their smart mobile phone apps for self-management and to remotely communicate with doctors and nurses.
In practice, the self-management and remote monitoring offers new ways of collaborating based on patient-centered-care. It is a way to continuously follow-up of the infants born very preterm symptoms and treatment effects - at the individual level in real time - against set treatment. The challenges are to develop useful and secure services for different groups related to the mobile-health platform. It involves continuous negotiation with people and organizations concerning how they should and could collaborate. This involves not just healthcare and patients but also patients’ families, EPR Vendors, quality register, researchers and IT industry. The need for the mobile-health platform as a service provided “by one body" has disappeared; today it is a shared platform embedded in the innovative patient and healthcare infrastructure. The mobile-health platform is just a starting point for a novel and limitless AI use as well as remote monitoring and self-management including limitless actors and activities on a national and international level.
The session will include: a) presentation of both the state of the art treatment of ROP and the results from the study, b) a description and a demo the m-health platform applied, and c) a parent's (of an infants born very preterm) description of how she has used the smart phone based app for education and communication with healthcare, also sharing her experience and perception of its use.
Klicka här för att se presentationen från detta seminarie